{"title":"Plasmapheresis in the dysproteinemias.","authors":"M. J. Drew","doi":"10.1046/J.1526-0968.2002.00393.X","DOIUrl":null,"url":null,"abstract":"The dysproteinemias consist of a broad range of serious disease states with the common thread of excessive production of an abnormal, or para-protein. Various clinical syndromes may arise, either from the underlying disease process, the excess paraprotein, or both. Clinical presentation depends upon the organ system(s) affected by the abnormal protein. Diseases included under the classification of dysproteinemias include cryoprotein-related diseases, Waldenström's macroglobulinemia, hyperviscosity syndrome, monoclonal gammopathy, multiple myeloma, light chain disease, and amyloidosis. Plasmapheresis, often in conjunction with other therapies, has been widely used to treat the dysproteinemias and their resulting clinical syndromes. Automated plasmapheresis, which separates plasma from the cellular blood elements by centrifugation, is used most commonly in the United States. Membrane separation and immunoadsorption techniques are more commonly used in Europe and Japan. In automated plasmapheresis, the plasma is removed from the patient's circulation and replaced with a protein-based fluid such as 5% human albumin solution or plasma protein fraction or with fresh frozen plasma. Membrane separation and immunoadsorption allow the offending proteins to be removed more selectively from the patient's plasma prior to the plasma being returned to the patient. This review article presents a description of each disease, the rationale for plasmapheresis therapy, recommended schedules of plasmapheresis, and the use of adjunctive therapies. Results of published studies, case reports, and the author's experience in treating these diseases will serve as the foundation for discussion.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2002-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"43","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1046/J.1526-0968.2002.00393.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 43

Abstract

The dysproteinemias consist of a broad range of serious disease states with the common thread of excessive production of an abnormal, or para-protein. Various clinical syndromes may arise, either from the underlying disease process, the excess paraprotein, or both. Clinical presentation depends upon the organ system(s) affected by the abnormal protein. Diseases included under the classification of dysproteinemias include cryoprotein-related diseases, Waldenström's macroglobulinemia, hyperviscosity syndrome, monoclonal gammopathy, multiple myeloma, light chain disease, and amyloidosis. Plasmapheresis, often in conjunction with other therapies, has been widely used to treat the dysproteinemias and their resulting clinical syndromes. Automated plasmapheresis, which separates plasma from the cellular blood elements by centrifugation, is used most commonly in the United States. Membrane separation and immunoadsorption techniques are more commonly used in Europe and Japan. In automated plasmapheresis, the plasma is removed from the patient's circulation and replaced with a protein-based fluid such as 5% human albumin solution or plasma protein fraction or with fresh frozen plasma. Membrane separation and immunoadsorption allow the offending proteins to be removed more selectively from the patient's plasma prior to the plasma being returned to the patient. This review article presents a description of each disease, the rationale for plasmapheresis therapy, recommended schedules of plasmapheresis, and the use of adjunctive therapies. Results of published studies, case reports, and the author's experience in treating these diseases will serve as the foundation for discussion.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血浆置换在蛋白异常血症中的作用。
蛋白异常贫血症包括一系列严重的疾病状态,其共同特征是异常蛋白或副蛋白的过量产生。各种临床综合征可能出现,要么来自潜在的疾病过程,过量的副蛋白,或两者兼而有之。临床表现取决于受异常蛋白影响的器官系统。蛋白异常血症分类下的疾病包括低温蛋白相关疾病、Waldenström大球蛋白血症、高黏度综合征、单克隆γ病、多发性骨髓瘤、轻链病和淀粉样变性。血浆置换通常与其他疗法联合使用,已被广泛用于治疗蛋白异常血症及其引起的临床综合征。自动血浆分离法,通过离心将血浆从细胞血液元素中分离出来,在美国最常用。膜分离和免疫吸附技术在欧洲和日本较为常用。在自动血浆置换术中,将血浆从患者循环中取出,并用蛋白质为基础的液体(如5%人白蛋白溶液或血浆蛋白部分)或新鲜冷冻血浆代替。膜分离和免疫吸附允许在血浆返回患者之前更有选择性地从患者血浆中去除有害蛋白。这篇综述文章介绍了每种疾病的描述,血浆置换治疗的基本原理,推荐的血浆置换方案,以及辅助治疗的使用。已发表的研究结果、病例报告和作者治疗这些疾病的经验将作为讨论的基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Presidential Address: PRESIDENTIAL ADDRESS Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Mobilization factors of peripheral blood stem cells in healthy donors. Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients. In vitro evaluation of newly developed adsorbent for selective removal of glycosylated low-density lipoprotein.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1